Strategy Driven

MAY 12, 2021

Unlike 3D films made for the cinema or stereoscopic televisions operating with glasses, such 3D displays require proprietary content combining as many as eight discrete images. There are already a dozen volumetric capture studios operating around the world that work by pointing dozens, even hundreds of cameras at a group on vast stages.

Technology 103

Technology Content Video Globalization 103

Tanveer Naseer

OCTOBER 20, 2015

The first leader was someone I worked with as part of the management team at a biotechnology firm, and how he guided our organization during the merger of our North American parent company with a much larger European multinational.

Power 100

Power Long-term Uncertainty Biotechnology 100

Harvard Business Review

MARCH 30, 2017

Looking at the executive teams we work with as consultants and those we teach in the classroom, increased diversity of gender, ethnicity, and age is apparent. Throughout this period, we have run a strategic execution exercise with executive groups focused on managing new, uncertain, and complex situations.

Diversity 8

Diversity Team Biotechnology Execution 8

Harvard Business Review

SEPTEMBER 11, 2014

For example, a wide variety of clean technologies (including wind, solar, and hydrogen) are vying to power vehicles and cities at the same time that a wide variety of medical technologies (chemical, biotechnological, genomic, and robotic) are being developed to treat diseases. Consider the 2×2 matrix below.

Uncertainty 21

Uncertainty Industry Bottom-up Technology 21

Harvard Business Review

SEPTEMBER 21, 2018

In contrast, 70% of respondents think their boards have effective processes for staying current on the company; 69% for compliance; 66% for financial planning; and 55% for risk management — although we should note that managing risks is a crucial consideration when pursuing innovation.

Innovation 9

Innovation Short-term Telecommunications Long-term 9

Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. To save the 20-year-old company, I had to get it operating like a start-up. Even individuals on NPS’s leadership team who didn’t embrace our values had to go.

Company 8

Company Pharmaceuticals Biotechnology Short-term 8

Harvard Business Review

FEBRUARY 17, 2011

The reason for the interest in in part because the industry has suffered from poor returns on investment over the last decade; indeed, some sectors, including biotechnology, report negative aggregate returns. In effect, the VCs at Nadathur Holdings serve as the executive team for a miniature healthcare innovation ecosystem.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15